Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Jacob Biotech Ltd. is currently prosecuting 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This activity is confined to a distinct examiner and 1 distinct art unit, showing a narrow administrative footprint for the company's active filings. Such a focused profile allows for a clear view of the current examination status.
The busiest examiner for this portfolio is LEE, WILLIAM Y, who holds the pending office action. This action constitutes the total pending workload for the company. With 1 distinct art unit involved, the prosecution remains concentrated within a specific technical group at the patent office.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEE, WILLIAM Y | 1 | 48.0% | +34.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16120346 | PHARMACEUTICAL PREPARATIONS OF SEBACOYL DINALBUPHINE AND ACETAMINOPHEN AND METHODS FOR TREATING PAIN | LEE, WILLIAM Y | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16120346 | PHARMACEUTICAL PREPARATIONS OF SEBACOYL DINALBUPHINE AND ACETAMINOPHEN AND METHODS FOR TREATING PAIN | LEE, WILLIAM Y | — |
| Art Unit | Apps |
|---|---|
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 16120346 | PHARMACEUTICAL PREPARATIONS OF SEBACOYL DINALBUPHINE AND ACETAMINOPHEN AND METHODS FOR TREATING PAIN | LEE, WILLIAM Y | 1623 | §103§112 | Non-Final OA | — | Pending | Sep 03, 2018 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialJacob Biotech Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
William Y Lee has the most, with 1 of Jacob Biotech Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
